Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Acute Myocardial Infarction Research, and Diabetes Treatment and Management.
Standardized Definitions of Changes in Kidney Function in Trials of Heart Failure
Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure
Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations
Comparative Effectiveness Research Using Randomized Trials and Observational Studies: Validity and Feasibility Considerations
Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial
Machine learning to optimize use of natriuretic peptides in the diagnosis of acute heart failure
Coordinated Expression of BMP10/ALK1/endoglin—Proteins that Drive Embryonic Cardiac and Vascular Morphogenesis—in Patients with Heart Failure: The EMPEROR Program
Abstract 4365761: Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants With Transthyretin Amyloid Cardiomyopathy Compared with Placebo, Independent of Atrial Fibrillation Status
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial
Efficacy, Safety and Mechanistic Impact of a Heart Failure Guideline-Directed Medical Therapy Clinic
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM
Lipoprotein(a), Oxidized Phospholipids, and Progression to Symptomatic Heart Failure: The CASABLANCA Study
Carbohydrate Antigen 125 Concentrations Across the Ejection Fraction Spectrum in Chronic Heart Failure: The EMPEROR Programme
Insulin-Like Growth Factor Binding Protein-7 Concentrations in Chronic Heart Failure: Results from the EMPEROR Programme
Racial Differences in Diabetic Cardiomyopathy
Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress Using NT-proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC
Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort